Our study was the first to investigate the co-expression of B7H3 and EGFR in NSCLC, with positive rates exceeding 50% across squamous carcinoma, adenocarcinoma, and EGFR-mutant subtypes. This evidence concerns the gene CD276 and adenocarcinoma.